trending Market Intelligence /marketintelligence/en/news-insights/trending/Xv2N0zbL6W4UnBGxpVB8mA2 content esgSubNav
In This List

Fluidigm files patent suit against IONpath over medical imaging technology

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Fluidigm files patent suit against IONpath over medical imaging technology

Fluidigm Corp. filed a patent infringement suit against privately held IonPath Inc. in a U.S. district court related to its proprietary imaging technology.

In the lawsuit, the mass cytometry and microfluidics technologies company alleged that IONpath's multiplexed ion beam imaging, or MIBI, technology infringes U.S. patents covering Fluidigm's mass cytometry, or CyTOF, technology.

The South San Francisco, Calif.-based company is seeking damages and injunctive relief requiring IONpath to stop selling its MIBI technology.

"Fluidigm has made substantial investments in the research and development of its CyTOF technology. This lawsuit is aimed at protecting those investments," Fluidigm CEO Chris Linthwaite said in a press release.